Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From ViiV Healthcare

Shionogi Still Hopeful For Xocova In US Despite Phase III Fail

Despite sales success in Japan and a fast track designation in the US, Shionogi’s oral COVID-19 therapeutic has missed statistical significance in a global Phase III trial in patients with mild to moderate symptoms.

Clinical Trials Coronavirus COVID-19

ViiV Healthcare And Medicines Patent Pool Celebrate 10-Year HIV Collaboration

On the heels of a decade-long partnership with ViiV Healthcare that has helped 24 million people with HIV, the Medicines Patent Pool introduces a new version of its patent database for essential medicines and COVID-19 vaccines.

Market Access Emerging Markets

Coming Of Age: Pharma’s Influencer Marketing Matures

Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.

Telehealth Ad Campaigns

Drug Advertising: NAD’s Clout In Rx Disputes Rising As It Builds Ties With Social Media Platforms, FDA

National Advertising Division’s voluntary, self-regulatory process is increasingly being used to vet competitor complaints over prescription drug ads. The group now has a reporting channel to Meta, which will take down disputed claims from social media sites, and is working to demonstrate the value of self-regulation to the FDA, NAD VP Brett says.

Ad Complaints Advertising, Marketing & Sales
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals